https://anavex.com/news/anavex-life-sciences-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-2024-2/2024-12-12T15:10:17-05:00https://anavex.com/news/anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimers-disease-to-ema-2/2024-12-12T15:10:54-05:00https://anavex.com/news/anavex-life-sciences-announces-acceptance-of-peer-reviewed-manuscript-of-oral-blarcamesine-phase-iib-iii-data-in-a-reference-alzheimers-disease-journal-2/2024-12-12T15:10:59-05:00https://anavex.com/news/anavexs-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimers-trial-data-presented-at-ctad-conference-2024-2/2024-12-12T15:11:10-05:00https://anavex.com/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/2024-12-12T15:13:06-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-2024/2024-12-12T15:11:16-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-third-quarter-financial-results-and-provides-business-update/2024-12-12T15:11:21-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-third-quarter-financial-results-on-tuesday-august-6-2024/2024-12-12T15:11:25-05:00https://anavex.com/news/anavex-life-sciences-announces-translational-biomarker-data-for-anavex2-73-blarcamesine-in-fragile-x-syndrome-major-cause-of-autism-at-the-19th-nfxf-international-fragile-x-conference/2024-12-12T15:11:31-05:00https://anavex.com/news/results-from-anavex-life-sciences-landmark-phase-iib-iii-trial-of-blarcamesine-presented-at-alzheimers-association-conference/2024-12-12T15:11:58-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference/2024-12-12T15:12:03-05:00https://anavex.com/news/anavex-life-sciences-announces-expansion-of-leadership-team/2024-12-12T15:12:08-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-2nd-bioconnect-investor-conference-at-nasdaq/2024-12-12T15:12:12-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-business-update/2024-12-12T15:12:17-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-second-quarter-financial-results-on-thursday-may-9th-2024/2024-12-12T15:12:21-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-conference/2024-12-12T15:12:26-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference/2024-12-12T15:12:30-05:00https://anavex.com/news/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex3-71-in-schizophrenia/2024-12-12T15:12:36-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-44th-annual-td-cowen-health-care-conference/2024-12-12T15:12:41-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-business-update/2024-12-12T15:12:46-05:00https://anavex.com/news/anavex-life-sciences-to-report-new-long-term-oral-blarcamesine-phase-iib-iii-alzheimers-disease-data-at-j-p-morgan-2025-healthcare-conference/2024-12-12T15:10:47-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2024-fourth-quarter-financial-results-on-monday-december-23-2024/2024-12-16T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-business-update/2024-12-23T07:25:00-05:00https://anavex.com/news/blarcamesine-receives-ema-filing-acceptance-for-treatment-of-alzheimers-disease/2024-12-23T06:55:00-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference/2025-01-06T07:25:00-05:00https://anavex.com/news/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blarcamesine-to-significantly-benefit-early-alzheimers-disease-patients/2025-01-13T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in-the-journal-of-prevention-of-alzheimers-disease/2025-01-15T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-announces-issuance-of-blarcamesine-anavex2-73-composition-of-matter-u-s-patent-expanding-its-intellectual-property-portfolio/2025-01-27T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-first-quarter-financial-results-on-wednesday-february-12-2025/2025-02-05T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-first-quarter-financial-results-and-provides-business-update/2025-02-12T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference/2025-02-24T07:25:00-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-24th-annual-needham-virtual-healthcare-conference/2025-12-08T14:24:19-05:00https://anavex.com/news/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-iib-iii-open-label-extension-trial-in-early-alzheimers-disease/2025-12-08T14:24:58-05:00https://anavex.com/news/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east/2025-12-08T14:26:34-05:00https://anavex.com/news/anavex-life-sciences-announces-appointment-of-dr-audrey-gabelle-md-phd-to-the-scientific-advisory-board/2025-12-08T14:33:10-05:00https://anavex.com/news/anavex-life-sciences-to-participate-in-the-citizens-life-sciences-conference/2025-12-08T14:34:14-05:00https://anavex.com/news/anavex-life-sciences-announces-full-enrollment-of-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/2025-12-08T14:35:33-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-second-quarter-financial-results-on-tuesday-may-13-2025/2025-12-08T14:36:28-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-second-quarter-financial-results-and-provides-business-update/2025-12-08T14:37:53-05:00https://anavex.com/news/anavex-life-sciences-to-participate-at-upcoming-healthcare-conferences/2025-12-08T14:39:35-05:00https://anavex.com/news/anavex-life-sciences-announces-positive-precision-medicine-results-from-up-to-4-years-of-oral-blarcamesine-treatment-in-phase-iib-iii-open-label-extension-trial-in-early-alzheimers-disease/2025-12-08T14:41:12-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-third-quarter-financial-results-on-tuesday-august-12-2025/2025-12-08T14:46:01-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-third-quarter-financial-results-and-provides-business-update/2025-12-08T14:48:54-05:00https://anavex.com/news/anavex-life-sciences-announces-new-publication-in-medical-journal-blarcamesine-prevented-cognitive-impairment-in-animal-model-of-alzheimers-disease/2025-12-08T15:35:05-05:00https://anavex.com/news/anavex-life-sciences-reports-new-publication-in-medical-journal-highlighting-the-established-precise-autophagy-mechanism-with-blarcamesine/2025-12-08T14:50:17-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-2025/2025-12-08T14:51:48-05:00https://anavex.com/news/anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approximating-normal-aging-in-new-precision-medicine-clinical-data-from-phase-iib-iii-alzheimers-disease-trial/2025-12-08T14:55:55-05:00https://anavex.com/news/anavex-life-sciences-announces-publication-of-oral-blarcamesine-describing-a-new-class-of-clinical-precision-medicine-from-phase-iib-iii-alzheimers-disease-trial/2025-12-08T14:57:37-05:00https://anavex.com/news/anavex-life-sciences-announces-successful-development-of-once-daily-oral-tablet-formulation-for-the-anavex3-71-program/2025-12-08T15:00:48-05:00https://anavex.com/news/anavex-life-sciences-announces-positive-topline-results-from-phase-2-study-of-anavex3-71-for-the-treatment-of-schizophrenia/2025-12-08T14:59:33-05:00https://anavex.com/news/anavex-life-sciences-announces-presentation-at-the-35th-alzheimer-europe-conference-connecting-science-and-communities-the-future-of-dementia-care/2025-12-08T15:01:50-05:00https://anavex.com/news/anavex-life-sciences-announces-continued-long-term-benefit-from-oral-blarcamesine-compared-to-decline-observed-in-the-alzheimers-disease-neuroimaging-initiative-adni-control-group/2025-12-08T15:03:59-05:00https://anavex.com/news/anavex-life-sciences-provides-regulatory-update-on-blarcamesine-for-early-alzheimers-disease/2025-12-08T15:05:09-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2025-fourth-quarter-financial-results-on-tuesday-november-25-2025/2025-12-08T15:06:15-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/2025-12-08T15:10:14-05:00https://anavex.com/news/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-update/2025-12-08T15:13:20-05:00https://anavex.com/news/anavex-life-sciences-to-present-oral-blarcamesine-data-at-the-18th-clinical-trials-on-alzheimers-disease-ctad-conference/2025-12-08T15:14:35-05:00https://anavex.com/news/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early-alzheimers-disease/2026-01-15T17:40:35-05:00https://anavex.com/news/anavex-life-sciences-submitted-request-for-ema-to-re-examine-its-opinion/2026-01-15T17:39:13-05:00https://anavex.com/news/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program/2026-01-15T17:34:42-05:00https://anavex.com/news/anavex-life-sciences-appoints-senior-vice-president-global-head-of-neurology/2026-01-15T17:33:24-05:00https://anavex.com/news/anavex-joins-access-ad-a-major-initiative-funded-by-the-european-commission-through-the-clinical-evaluation-of-blarcamesine-as-part-of-a-precision-medicine-approach-in-alzheimers-disease/2026-01-15T17:31:20-05:00https://anavex.com/news/anavex-life-sciences-to-announce-fiscal-2026-first-quarter-financial-results-on-monday-february-9-2026/2026-02-09T09:16:16-05:00https://anavex.com/news/anavex-life-sciences-q1-2026-financial-results/2026-02-08T23:27:51-05:00https://anavex.com/news/anavex-life-sciences-appoints-dr-axel-paeger-board-of-directors/2026-02-23T07:36:43-05:00https://anavex.com/news/anavex-presents-td-cowen-health-care-conference-2026/2026-02-25T07:07:28-05:00https://anavex.com/news/anavex-life-sciences-to-present-at-the-citizens-life-sciences-conference/2026-03-02T19:43:19-05:00https://anavex.com/news/anavex-blarcamesine-parkinsons-adpd-2026/2026-03-17T07:31:00-04:00https://anavex.com/news/anavex-blarcamesine-autophagy-alzheimers/2026-03-20T00:37:27-04:00https://anavex.com/news/anavex-blarcamesine-brain-volume-alzheimers-adpd-2026/2026-03-23T07:29:06-04:00https://anavex.com/news/anavex-blarcamesine-eu-regulatory-update-alzheimers/2026-03-24T21:31:14-04:00https://anavex.com/news/anavex-regulatory-update-blarcamesine-alzheimers/2026-03-29T09:18:11-04:00https://anavex.com/news/anavex-needham-healthcare-conference-2026/2026-04-06T22:54:15-04:00https://anavex.com/news/anavex-autophagy-autism-alzheimers-blarcamesine/2026-04-14T00:00:26-04:00https://anavex.com/news/anavex-appoints-terrie-kellmeyer-interim-ceo/2026-05-05T21:59:17-04:00https://anavex.com/news/anavex-life-sciences-receives-expected-nasdaq-delinquency-notification/2026-05-21T22:36:31-04:00https://anavex.com/news/anavex-life-sciences-reports-preliminary-second-quarter-2026-financial-results-and-provides-business-update/2026-07-30T15:02:18-04:00https://anavex.com/news/anavex-life-sciences-announces-plans-to-refresh-board-to-continue-overseeing-critical-progress-and-stockholder-value-creation/2026-08-03T08:22:26-04:00https://anavex.com/news/anavex-life-sciences-highlights-highly-qualified-board-and-decisive-actions-to-create-long-term-value-for-stockholders/2026-08-11T08:44:35-04:00https://anavex.com/news/anavex-life-sciences-mails-letter-to-stockholders-reinforcing-relevant-experience-of-all-six-director-nominees/2026-08-17T08:36:12-04:00https://anavex.com/news/anavex-life-sciences-reports-third-fiscal-quarter-2026-financial-results-and-business-update/2026-08-25T08:25:05-04:00https://anavex.com/news/anavex-life-sciences-regains-compliance-with-nasdaq-periodic-filing-requirement/2026-09-02T16:03:44-04:00https://anavex.com/news/anavex-life-sciences-to-host-investor-call-on-wednesday-september-9-2026-at-400-pm-et/2026-09-09T16:38:37-04:00https://anavex.com/news/leading-independent-proxy-advisory-firm-iss-recommends-stockholders-vote-for-all-six-of-anavexs-highly-qualified-director-nominees/2026-09-14T08:38:12-04:00https://anavex.com/news/leading-independent-proxy-advisory-firm-iss-recommends-stockholders-vote-for-all-six-of-anavexs-highly-qualified-director-nominees-2/2026-09-24T10:27:45-04:00https://anavex.com/news/anavex-receives-fda-clearance-of-its-ind-application-for-blarcamesine-in-fragile-x-syndrome/2026-10-15T18:25:52-04:00https://anavex.com/news/anavex-provides-corporate-update-announces-completion-of-clinical-conduct-of-adme-and-ddi-clinical-studies/2026-10-20T17:10:26-04:00https://anavex.com/fiscal/anavex-life-sciences-names-terrie-kellmeyer-ph-d-as-president-and-chief-executive-officer-and-member-of-the-board-of-directors/2026-11-03T13:52:19-05:00